Left Atrial Appendage Closure

The left atrial appendage (LAA) of the heart is a common location where clots form in atrial fibrillation (AFib) patients that then embolism and cause a stroke. Closing off the LAA either surgically, with a clip or via transcatheter LAA closure device, closes the opening to the LAA to prevent clots from forming or embolizing. The clots are the reason why AFib patients need to be on anticoagulants. LAA occlusion (LAAO) enables patients to stop taking anticoagulation drugs. LAAO has been a rapidly growing segment of structural heart procedures since the approval of the first device, the Watchman, in 2015. Procedures are performed by electrophysiologists, interventional cardiologist or cardiac surgeons.

Two examples of new left atrial appendage occluders (LAAO), the Conformal omn left and the Laminar on the right. evi Nair, MD, FACC, FHRS, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit. #TVT #TVT2020 #LAA #LAAO #EPeeps

VIDEO: Advances in left atrial appendage occlusion technology

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

Thumbnail

What peridevice leaks after LAAO mean for patient health

The study's authors reviewed data from more than 50,000 patients, presenting their findings in JACC: Clinical Electrophysiology.

Thumbnail

Real-world Watchman patients experiencing fewer complications after LAAO than seen in clinical trials

The study's authors compared findings from the PROTECT-AF and PREVAIL clinical trials with data from the NCDR LAAO Registry, focusing on short-term and long-term outcomes. 

Amulet vs. Watchman: LAA occluder devices compared in new head-to-head trial

The Amulet's implantation success rate and LAA closure rate were both higher than the first-generation Watchman device, researchers reported.

Abbott’s LAA closure solution for AFib patients gains FDA approval

The device has already been approved in other parts of the world, including Europe.